Search research articles
Contact Us
Filters
Showing results (81-90 of 114) with videos related to
Page
of 12
Sort By:
Breast Cancer Research and Treatment
|
July 29, 2017
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers
Cesar A Santa-Maria, Megan Kruse, Paola Raska, et al.
Breast Cancer : Basic and Clinical Research
|
April 30, 2015
Defining the survival benchmark for breast cancer patients with systemic relapse
Simon B Zeichner, Tadeu Ambros, John Zaravinos, et al.
Immunologic Research
|
November 13, 2013
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L
C Marcela Díaz-Montero, Abdel-Aziz Zidan, Maria F Pallin, et al.
Clinical Breast Cancer
|
November 6, 2021
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
Hanjie Mo, Catherine E Renna, Halle C F Moore, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 10, 2025
Stakeholder perspectives on the role of caregivers in cancer clinical trial decision-making: results of a qualitative study
Eric C Blackstone, Susan R Mazanec, Barbara J Daly, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 10, 2009
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
Mohamed L Salem, C Marcela Díaz-Montero, Amir A Al-Khami, et al.
Breast Cancer Research and Treatment
|
June 22, 2016
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
Shruti R Tiwari, Prasun Mishra, Paola Raska, et al.
American Journal of Clinical Oncology
|
February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
Peter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Breast Cancer Research : BCR
|
June 20, 2026
Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer
Nickolas Stabellini, Sonia D de Oliveira, Takae Mizukami, et al.
Journal of Translational Medicine
|
March 19, 2013
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
Claudia Marcela Diaz, Alberto Chiappori, Luigi Aurisicchio, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 114) with videos related to
Sort By:
Page
of 12
Breast Cancer Research and Treatment
|
July 29, 2017
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers
Cesar A Santa-Maria, Megan Kruse, Paola Raska, et al.
Breast Cancer : Basic and Clinical Research
|
April 30, 2015
Defining the survival benchmark for breast cancer patients with systemic relapse
Simon B Zeichner, Tadeu Ambros, John Zaravinos, et al.
Immunologic Research
|
November 13, 2013
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L
C Marcela Díaz-Montero, Abdel-Aziz Zidan, Maria F Pallin, et al.
Clinical Breast Cancer
|
November 6, 2021
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
Hanjie Mo, Catherine E Renna, Halle C F Moore, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 10, 2025
Stakeholder perspectives on the role of caregivers in cancer clinical trial decision-making: results of a qualitative study
Eric C Blackstone, Susan R Mazanec, Barbara J Daly, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 10, 2009
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
Mohamed L Salem, C Marcela Díaz-Montero, Amir A Al-Khami, et al.
Breast Cancer Research and Treatment
|
June 22, 2016
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
Shruti R Tiwari, Prasun Mishra, Paola Raska, et al.
American Journal of Clinical Oncology
|
February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
Peter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Breast Cancer Research : BCR
|
June 20, 2026
Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer
Nickolas Stabellini, Sonia D de Oliveira, Takae Mizukami, et al.
Journal of Translational Medicine
|
March 19, 2013
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
Claudia Marcela Diaz, Alberto Chiappori, Luigi Aurisicchio, et al.
Page
of 12